Eplontersen

WAINUA is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear.

Drug facts

Used for: WAINUA is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

What it is used for

WAINUA is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. WAINUA is a transthyretin-directed antisense oligonucleotide indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Cite this page

NLM: sofidex [Internet]. Daloreum; c2026. Eplontersen; [reviewed 2026 Aug 2; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/eplontersen
APA 7th: sofidex. (2026, August 2). Eplontersen. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/eplontersen
AMA 11th: Eplontersen. sofidex. Reviewed August 2, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/eplontersen

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.